You just read:

Apexigen, Inc. Announces First Patient Dosed in Phase 1b/2 Clinical Trial of APX005M in Combination with Opdivo (nivolumab) in Advanced Solid Tumors

News provided by

Apexigen, Inc.

Jul 17, 2017, 07:00 ET